Evolus

Q3 FY2026 EarningsQ3 FY26 results slightly beat consensus on the top line ($78.0M vs. $77.6M) while achieving a fourth consecutive quarter of positive Adjusted EBITDA ($1.2M). GAAP EPS of -$0.19 missed the mean estimate of -$0.17 but remained within the analyst range, primarily due to non-cash revaluations and interest expenses. The HA gel portfolio was a standout, growing 40% YoY, while management reaffirmed full-year revenue guidance and slightly improved its operating expense outlook.